Massive human-chain formed in Tirunelveli to combat drug abuse, alcoholism, and communal disharmony.
PorAinvest
miércoles, 13 de agosto de 2025, 12:32 pm ET1 min de lectura
LLY--
Mounjaro Kwikpen is available in six dose strengths ranging from 2.5 mg to 15 mg, with pricing varying from 14,000 to 27,500 rupees per month. The smallest doses are priced at 14,000 rupees and 17,500 rupees, while the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses are priced at 27,500 rupees [1].
Novo Nordisk's Wegovy, also a GLP-1 receptor agonist, has smaller doses ranging from 0.25 mg to 2.4 mg, priced between 17,345 to 26,015 rupees per month. The highest doses of Mounjaro are priced more competitively compared to Wegovy [1].
Lilly began selling Mounjaro in India in late March for diabetes and obesity management in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since their launch, with sales in July doubling month-on-month [1].
The human-chain organized by the Forum for Social Harmony in Tirunelveli, India, aimed to raise awareness about drug abuse, alcoholism, and communal disharmony. The event, which saw participation from over 3,000 students and activists, was inaugurated by Assistant Collector Dhawlendu [2].
References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-launches-mounjaro-pen-india-160-starting-dose-stepping-up-novo-rivalry-2025-08-13/
[2] https://www.thehindu.com/news/cities/Madurai/human-chain-against-drug-abuse-alcoholism/article69929982.ece
NVO--
A human-chain was organized by the Forum for Social Harmony in Tirunelveli, India, to raise awareness about drug abuse, alcoholism, and communal disharmony. Over 3,000 students and activists participated in the event, which was inaugurated by Assistant Collector Dhawlendu. The event aimed to foster communal harmony and promote a drug-free and alcohol-free society.
Eli Lilly (LLY.N) has recently launched its Mounjaro Kwikpen, a once-weekly injection device, in India. This move is part of the company's strategy to compete with Novo Nordisk (NOVOb.CO) in the market for weight-loss and diabetes management drugs. The launch follows a similar pen device launch by Novo Nordisk, Wegovy, in India.Mounjaro Kwikpen is available in six dose strengths ranging from 2.5 mg to 15 mg, with pricing varying from 14,000 to 27,500 rupees per month. The smallest doses are priced at 14,000 rupees and 17,500 rupees, while the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses are priced at 27,500 rupees [1].
Novo Nordisk's Wegovy, also a GLP-1 receptor agonist, has smaller doses ranging from 0.25 mg to 2.4 mg, priced between 17,345 to 26,015 rupees per month. The highest doses of Mounjaro are priced more competitively compared to Wegovy [1].
Lilly began selling Mounjaro in India in late March for diabetes and obesity management in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since their launch, with sales in July doubling month-on-month [1].
The human-chain organized by the Forum for Social Harmony in Tirunelveli, India, aimed to raise awareness about drug abuse, alcoholism, and communal disharmony. The event, which saw participation from over 3,000 students and activists, was inaugurated by Assistant Collector Dhawlendu [2].
References:
[1] https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-launches-mounjaro-pen-india-160-starting-dose-stepping-up-novo-rivalry-2025-08-13/
[2] https://www.thehindu.com/news/cities/Madurai/human-chain-against-drug-abuse-alcoholism/article69929982.ece

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios